NOXA as critical mediator for drug combinations in polychemotherapy

Cell Death and Disease

Volumn 3, Issue 6, 2012, Pages

  Ehrhardt, H ^a,b   Hofig I ^a   Wachter, F ^a   Obexer, P ^c   Fulda, S ^d   Terziyska, N ^a   Jeremias, I ^a,b  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^d GOETHE UNIVERSITY   (Germany)

Author keywords

betulinic acid; doxorubicin; NOXA; p53; PUMA

Indexed keywords

ACETYLCYSTEINE; APOPTOSIS INDUCING FACTOR; BETULIC ACID; BIM PROTEIN; CASPASE; CASPASE 3; CASPASE 6; CASPASE 7; CASPASE 8; CASPASE 9; CYCLOHEXIMIDE; CYTOCHROME C; DACTINOMYCIN; DOXORUBICIN; ENDONUCLEASE G; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HISTONE H1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAK; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN BID; PROTEIN MCL 1; PROTEIN NOXA; PROTEIN P53; PUMA PROTEIN; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; UNINDEXED DRUG; VINCRISTINE; X LINKED INHIBITOR OF APOPTOSIS;

ACUTE LEUKEMIA; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVATION; ENZYME RELEASE; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN FAMILY; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84863450256     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.53     Document Type: Article

References (40)

1. Suzuki S, Nakasato M, Shibue T, Koshima I, Tanigushi T. Therapeutic potential of proapoptotic molecule Noxa in the selective elimination of tumor cells. Cancer Sci 2009; 100: 759-769.
2. Zhang L, Lopez H, George NM, Liu X, Pang X, Luo X. Selective involvement of BH3-only proteins and differential targets of Noxa in diverse apoptotic pathways. Cell Death Differ 2010; 18: 864-873.
3. Labi V, Erlacher M, Kiessling S, Villunger A. BH3-only proteins in cell death initiation, malignant disease and anticancer therapy. Cell Death Differ 2006; 13: 1325-1338.
4. Ploner C, Kofler R, Villunger A. NOXA: At the tip of the balance between life and death. Oncogene 2009; 27: S84-S92.
5. Shibue T, Taniguchi T. BH3-only proteins: Integrated control point of apoptosis. Int J Cancer 2006; 119: 2036-2043.
6. Sheridan C, Brumatti G, Elgendy M, Brunet M, Martin SJ, An ERK. dependent pathway to Noxa expression regulates apoptosis by platinum-based chemotherapeutic drugs. Oncogene 2010; 29: 6428-6441.
7. Tonino SH, van Laar J, van Oers MH, Wang JY, Eldering E, Kater AP. ROS-mediated upregulation of NOXA overcomes chemoresistance in chronic lymphocytic leukemia. Oncogene 2010; 30: 701-713.
8. Pérez-Galán P, Roué G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomibe induces apoptosis in mantle-cell lymphoma through generation of ROS and NOXA activation independent of p53 status. Blood 2006; 107: 257-264.
9. Yu J, Zhang L. PUMA, a potent killer with or without p53. Oncogene 2009; 27: S71-S83.
10. Ehrhardt H, Fulda S, Führer M, Debatin KM, Jeremias I. Betulinic acid-induced apoptosis in leukaemia cells. Leukemia 2004; 18: 1406-1412.
11. Fulda S. Betulinic acid: A natural product with anticancer activity. Mol Nutr Food Res 2009; 53: 140-146.
12. Fulda S, Friesen C, Los M, Scaffidi C, Mier W, Benedict M et al. Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors. Cancer Res 1997; 57: 4956-4964.
13. Fulda S, Scaffidi C, Susin SA, Krammer PH, Kroemer G, Peter ME et al. Activation of mitochondria and release of mitochondrial apoptogenetic factors by betulinic acid. J Biol Chem 1998; 273: 33942-33948.
14. Wick W, Grimmel C, Wagenknecht B, Dichgans J, Weller M. Betulinic acid-induced apoptosis in glioma cells: A sequential requirement for new protein synthesis, formation of reactive oxygen species, and caspase processing. J Pharmacol Exp Ther 1999; 289: 1306-1312.
15. Estlin EJ, Ronghe M, Burke GA, Yule SM. The clinical and cellular pharmacology of vincristine, corticosteroids, L-Asparaginase, anthracyclines and cyclophosphamide in relation to childhood acute lymphoblastic leukaemia. Br J Haematol 2000; 110: 780-790.
16. Shin YG, Cho KH, Chung SM, Graham J, Das Gupta TK, Pezzuto JM. Determination of betulinic acid in mouse blood, tumor and tissue homogenates by liquid chromatographyelectrospray mass spectrometry. J Chromatogr B Biomed Sci Appl 1999; 732: 331-336.
17. Gamen S, Anel A, Pérez-Galán P, Lasierra P, Johnson D, Piñeiro A et al. Doxorubicin treatment activates a Z-VAD-sensitive caspase, which causes deltapsim loss, caspase-9 activity, and apoptosis in Jurkat cells. Exp Cell Res 2000; 258: 223-235.
18. Ballestrero A, Nencioni A, Boy D, Rocco I, Garuti A, Mela GS et al. Tumor necrosis factorrelated apoptosis-inducing ligand cooperates with anticancer drugs to overcome chemoresistance in antiapoptotic Bcl-2 family members expressing jurkat cells. Clin Cancer Res 2004; 10: 1463-1470.
19. López-Royuela N, Pérez-Galán P, Galán-Malo P, Yuste VJ, Anel A, Susín SA et al. Different contribution of BH3-only proteins and caspases to doxorubicin-induced apoptosis in p53-deficient leukemia cells. Biochem Pharmacol 2010; 79: 1746-1758.
20. Letai AG. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer 2008; 8: 121-132.
21. Youle RJ, Strasser A. The BCL-2 protein family: Opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47-59.
22. Resnick-Silverman L, Manfredi JJ. Gene-specific mechanisms of p53 transcriptional control and prospects for cancer therapy. J Cell Biochem 2006; 99: 679-689.
23. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Hum Mutat 2007; 28: 622-629.
24. Ehrhardt H, Wachter F, Maurer M, Stahnke K, Jeremias I. Important role of Caspase-8 for chemo-sensitivity of ALL cells. Clin Cancer Res 2011; 17: 7605-7613.
25. Ehrhardt H, Schrembs D, Moritz C, Wachter F, Haldar S, Graubner U et al. Optimized antitumor effects of anthracyclines plus vinca alkaloids using a novel, mechanism-based application schedule. Blood 2011; 118: 6123-6113.
26. Ehrhardt H, Haecker S, Wittmann S, Maurer M, Borkhardt A, Toloczko A et al. Cytotoxic drug-induced, p53-mediated upregulation of Caspase-8 in tumor cells. Oncogene 2008; 27: 783-793.
27. Greshock J, Nathanson K, Martin AM, Zhang L, Coukos G, Weber BL et al. Cancer cell lines as genetic models of their parent histology: Analyses based on array comparative genomic hybridization. Cancer Res 2007; 67: 3594-3600.
28. Sandberg R, Ernberg I. Assessment of tumor characteristic gene expression in cell lines using a tissue similarity index (TSI).Proc Natl Acad Sci USA 2005; 102: 2052-2057.
29. Peller S, Rotter V. TP53 in hematological cancer: Low incidence of mutations with significant clinical relevance. Hum Mutat 2003; 21: 277-284.
30. Royds JA, Iacopetta B. p53 and disease: When the guardian angel fails. Cell Death Differ 2006; 13: 1017-1026.
31. Blagosklonny MV. p53: An ubiquitous target of anticancer drugs. Int J Cancer 2002; 98: 161-166.
32. Joerger AC, Fersht AR. Structure-function-rescue: The diverse nature of common p53 cancer mutants. Oncogene 2007; 26: 2226-2242.
33. Sawada N, Kataoka K, Kondo K, Arimochi H, Fujino H, Takahashi Y et al. Betulinic acid augments the inhibitory effects of vincristine on growth and lung metastasis of B16F10 melanoma cells in mice. Br J Cancer 2004; 90: 1672-1678.
34. Selzer E, Pimentel E, Wacheck V, Schlegel W, Pehamberger H, Jansen B et al. Effects of betulinic acid alone and in combination with irradiation in human melanoma cells. J Invest Dermatol 2000; 114: 935-940.
35. Baader E, Toloczko A, Fuchs U, Schmid I, Beltinger C, Ehrhardt H et al. TRAIL-mediated proliferation of tumor cells with receptor-close apoptosis defects. Cancer Res 2005; 65: 7888-7895.
36. Ehrhardt H, Fulda S, Schmid I, Hiscott J, Debatin KM, Jeremias I. TRAIL-induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NFkB. Oncogene 2003; 22: 3842-3852.
37. Gao Z, Shao Y, Jiang X. Essential roles of the Bcl-2 family of proteins in caspase-2-induced apoptosis. J Biol Chem 2005; 280: 38271-38275.
38. Obexer P, Geiger K, Ambros PF, Meister B, Ausserlechner MJ. FKHRL1-mediated expression of Noxa and Bim induces apoptosis via the mitochondria in neuroblastoma cells. Cell Death Differ 2007; 14: 534-547.
39. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev Immunol 2007; 7: 118-130.
40. Höfig I, Ehrhardt H, Jeremias I. Efficient RNA interference in patientśacute lymphoblastic leukemia cells amplified as xenografts in mice. Cell Commun Signal 2012; 10: 8.